Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Tianlei Ying and Yanling Wu.
Connection Strength

4.289
  1. Identification of Human Single-Domain Antibodies against SARS-CoV-2. Cell Host Microbe. 2020 06 10; 27(6):891-898.e5.
    View in: PubMed
    Score: 0.882
  2. Single-Domain Antibodies As Therapeutics against Human Viral Diseases. Front Immunol. 2017; 8:1802.
    View in: PubMed
    Score: 0.746
  3. Neutralization of Zika virus by germline-like human monoclonal antibodies targeting cryptic epitopes on envelope domain III. Emerg Microbes Infect. 2017 Oct 11; 6(10):e89.
    View in: PubMed
    Score: 0.737
  4. Potent germline-like monoclonal antibodies: rapid identification of promising candidates for antibody-based antiviral therapy. Antib Ther. 2021 Apr; 4(2):89-98.
    View in: PubMed
    Score: 0.236
  5. The impact of receptor-binding domain natural mutations on antibody recognition of SARS-CoV-2. Signal Transduct Target Ther. 2021 03 23; 6(1):132.
    View in: PubMed
    Score: 0.234
  6. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect. 2020; 9(1):382-385.
    View in: PubMed
    Score: 0.217
  7. Engineering a Novel Antibody-Peptide Bispecific Fusion Protein Against MERS-CoV. Antibodies (Basel). 2019 Nov 04; 8(4).
    View in: PubMed
    Score: 0.213
  8. In-Depth Analysis of Human Neonatal and Adult IgM Antibody Repertoires. Front Immunol. 2018; 9:128.
    View in: PubMed
    Score: 0.188
  9. Engineered Soluble Monomeric IgG1 Fc with Significantly Decreased Non-Specific Binding. Front Immunol. 2017; 8:1545.
    View in: PubMed
    Score: 0.185
  10. A Potent Germline-like Human Monoclonal Antibody Targets a pH-Sensitive Epitope on H7N9 Influenza Hemagglutinin. Cell Host Microbe. 2017 Oct 11; 22(4):471-483.e5.
    View in: PubMed
    Score: 0.184
  11. Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD. Cell Rep. 2021 02 02; 34(5):108699.
    View in: PubMed
    Score: 0.058
  12. RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response. Signal Transduct Target Ther. 2020 11 27; 5(1):282.
    View in: PubMed
    Score: 0.057
  13. Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in COVID-19 patients. Cell Mol Immunol. 2020 10; 17(10):1095-1097.
    View in: PubMed
    Score: 0.056
  14. Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection. Cell Rep. 2020 07 21; 32(3):107918.
    View in: PubMed
    Score: 0.056
  15. Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. Cell Mol Immunol. 2020 07; 17(7):765-767.
    View in: PubMed
    Score: 0.054
  16. A defucosylated bispecific multivalent molecule exhibits broad HIV-1-neutralizing activity and enhanced antibody-dependent cellular cytotoxicity against reactivated HIV-1 latently infected cells. AIDS. 2018 08 24; 32(13):1749-1761.
    View in: PubMed
    Score: 0.049
  17. Potent In Vivo NK Cell-Mediated Elimination of HIV-1-Infected Cells Mobilized by a gp120-Bispecific and Hexavalent Broadly Neutralizing Fusion Protein. J Virol. 2017 10 15; 91(20).
    View in: PubMed
    Score: 0.046
  18. One-domain CD4 Fused to Human Anti-CD16 Antibody Domain Mediates Effective Killing of HIV-1-Infected Cells. Sci Rep. 2017 08 22; 7(1):9130.
    View in: PubMed
    Score: 0.046
  19. Escape from humoral immunity is associated with treatment failure in HIV-1-infected patients receiving long-term antiretroviral therapy. Sci Rep. 2017 07 24; 7(1):6222.
    View in: PubMed
    Score: 0.045
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.